Lobe Sciences Current Ratio vs. Current Valuation

LOBEF Stock  USD 0.01  0.01  950.00%   
Based on Lobe Sciences' profitability indicators, Lobe Sciences may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Lobe Sciences' ability to earn profits and add value for shareholders.
For Lobe Sciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lobe Sciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lobe Sciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lobe Sciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lobe Sciences over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Lobe Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lobe Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lobe Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lobe Sciences Current Valuation vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lobe Sciences's current stock value. Our valuation model uses many indicators to compare Lobe Sciences value to that of its competitors to determine the firm's financial worth.
Lobe Sciences is rated fourth overall in current ratio category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lobe Sciences' earnings, one of the primary drivers of an investment's value.

Lobe Current Valuation vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Lobe Sciences

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
2.23 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Lobe Sciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(6.77 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Lobe Current Valuation vs Competition

Lobe Sciences is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is now estimated at about 1.09 Billion. Lobe Sciences has negative current valuation of (6.77 Million) having no influence on the industry.

Lobe Sciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lobe Sciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lobe Sciences will eventually generate negative long term returns. The profitability progress is the general direction of Lobe Sciences' change in net profit over the period of time. It can combine multiple indicators of Lobe Sciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences is traded on OTC Exchange in the United States.

Lobe Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lobe Sciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lobe Sciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lobe Sciences' important profitability drivers and their relationship over time.

Use Lobe Sciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lobe Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lobe Sciences will appreciate offsetting losses from the drop in the long position's value.

Lobe Sciences Pair Trading

Lobe Sciences Pair Trading Analysis

The ability to find closely correlated positions to Lobe Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lobe Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lobe Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lobe Sciences to buy it.
The correlation of Lobe Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lobe Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lobe Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lobe Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Lobe Sciences position

In addition to having Lobe Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Lobe OTC Stock

To fully project Lobe Sciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lobe Sciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lobe Sciences' income statement, its balance sheet, and the statement of cash flows.
Potential Lobe Sciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Lobe Sciences investors may work on each financial statement separately, they are all related. The changes in Lobe Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lobe Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.